Class Action Lawsuit Filed Against GSK plc: What Investors Need to Know
New York, NY – Levi & Korsinsky, LLP announces that a class action securities lawsuit has been filed on behalf of shareholders who purchased GSK plc (“GSK” or the “Company”) (NYSE: GSK) common stock between February 19, 2020, and March 17, 2025. The lawsuit was filed in the United States District Court for the Southern District of New York and alleges that the Company and certain of its top executives violated the Securities Exchange Act of 1934.
Allegations Against GSK
The complaint alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that:
- GSK’s HIV drug, Sabril, was experiencing significant sales declines due to safety concerns;
- The Company was experiencing increased competition in its respiratory business;
- GSK’s R&D pipeline was not as strong as represented;
- The Company was experiencing delays in its planned separation of its pharmaceutical and consumer healthcare businesses.
Impact on Individual Investors
If you purchased GSK common stock during the Class Period, you may be entitled to recover your losses, including damages. To obtain more information, you can contact Levi & Korsinsky, LLP.
Impact on the World
The class action lawsuit against GSK may have significant implications for the pharmaceutical industry as a whole. If the allegations are proven true, it could lead to increased scrutiny of other companies in the sector, particularly those with significant R&D pipelines and complex business models.
Conclusion
This is not the first time GSK has faced securities litigation, but the allegations in this latest lawsuit are serious and could have significant consequences for the Company and its investors. As the case progresses, it will be important for investors to stay informed about developments and potential implications for their investments. Levi & Korsinsky, LLP will continue to monitor the situation closely and provide updates as new information becomes available.
Investors who purchased GSK common stock during the Class Period may have legal claims and are encouraged to contact Levi & Korsinsky, LLP to discuss their options for recovering their losses.
About Levi & Korsinsky, LLP
Levi & Korsinsky, LLP is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, accounting fraud, and consumer protection violations. For more information, please visit www.zlk.com.
